Proposed FDA/Industry "Least Burdensome" Panel Will Not Include Agency
This article was originally published in The Gray Sheet
An industry-only task force will be charged with drafting tentative guidelines to outline "least burdensome" avenues for industry and FDA reviewers in the submission of premarket applications, industry reps and FDA concluded at a Jan. 4 meeting in Rockville, Maryand.
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.